Abstract
Background Dietary magnesium and serum magnesium play an important part in cardiovascular disease (CVD). However, the correlation between magnesium depletion score (MDS) and the development and CVD prognosis remains unclear. This analysis examines the cross-sectional relationship between MDS and CVD, and the longitudinal correlation between MDS and all-cause and cardiovascular mortality in CVD individuals.
Methods In all, 42,711 individuals were selected from the National Health and Nutrition Examination Survey, including 5,015 subjects with CVD. The correlation between MDS and total and individual CVD was examined using the survey-weighted multiple logistic regression analysis. Among 5,011 CVD patients, 2,285 and 927 participants were recorded with all-cause and cardiovascular deaths, respectively. We applied survey-weighted Cox proportional hazards regression analyses to investigate the impact of MDS on the mortality of CVD individuals.
Results CVD group had higher MDS levels than the non-CVD groups. After controlling all confounding factors, individuals with MDS scored 1-2, and ≥3 had higher odds of total CVD and specific CVD than those with MDS scored 0. The relationship between MDS and total CVD was stable and significant in all subgroups. The fully adjusted Cox regression model presented that the risk of all-cause and cardiovascular deaths increased 2.41 and 2.00 times in participants with MDS≥3 compared to those with MDS scored 0.
Conclusions MDS is a vital risk factor for CVD’s prevalence and all-cause and cardiovascular deaths.
What is new?
MDS is a significant positive correlation with CVD’s prevalence in US adults.
High MDS markedly elevated the risk of all-cause and cardiovascular deaths among participants with CVD.
What are the clinical implications?
MDS can be used to evaluate the prevention and prognosis of cardiovascular diseases.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This study is retrospective and does not require clinical registration.
Funding Statement
This research was funded by National Natural Science Foundation of China, grant number 82270506.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NHANES has acquired written informed consent from each participant. Approval was obtained from the Research Ethics Review Board of the National Center for Health Statistics (NCHS). Therefore, no additional ethical approval was needed for this analysis.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
All data can be obtained from NHANES official (website https://www.cdc.gov/nchs/nhanes/index.htm).
